Experienced in Disseminated Intravascular Coagulation

Min H. Tao

Hefei, CN 
Experienced in Disseminated Intravascular Coagulation
Hefei, CN 
OverviewLocationsClinical Research

Overview

Min Tao practices in Hefei, China. Tao is rated as an Experienced expert by MediFind in the treatment of Disseminated Intravascular Coagulation. Their top areas of expertise are Stomach Cancer, Pancreatic Cancer, Secondary Peritonitis, Hepato-Pancreato-Biliary Surgery, and Gastrectomy.

Their clinical research consists of co-authoring 216 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Disseminated Intravascular Coagulation.

Locations

Hefei, 230601, China
Other Locations
Suzhou, 215123, China
Wuhu, 241003, China
Beijing, China
Nanjing, China
Shanghai, 200433, China
Tianjin, 300350, China
Bengbu, China
Dalian, 116622, China
State Key Laboratory Of Freshwater Ecology And Biotechnology, Wuhan, 430072, China
Hangzhou, China
Wuxi, China
Tongji, China
China
Bengbu, 233004, China
Dalian, China
Changzhou, 213003, China
Huangshi, China
Key Laboratory Of Watershed Geographic Sciences, Nanjing, 210008, China
Taizhou, 318020, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Tislelizumab+Cisplatin or Carboplatin+Pemetrexed, Cisplatin or Carboplatin+Pemetrexed
Study Phase: Phase 3
Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial
Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: Icaritin, Sorafenib Tosylate Tablets
Study Phase: Phase 3
View 1 Less Clinical Trial

216 Total Publications

MAN1A1 promotes colorectal cancer liver metastasis by maintaining TGFBR2 protein stability.
MAN1A1 promotes colorectal cancer liver metastasis by maintaining TGFBR2 protein stability.
Journal: Acta biochimica et biophysica Sinica
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tao's expertise for a condition
ConditionClose
      View All 35 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile